Prolymphocytic leukaemia of B‐ and T‐cell subtype: a state‐of‐the‐art paper
Prolymphocytic leukaemias of B and T cell subtype are rare diseases. Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor. Purine analogues and monoclonal antibodies have shown efficacy in B‐cell prolymphocytic leukaemia although further studies are warranted. Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T‐cell prolymphocytic leukaemia (T‐PLL) but responses are still transient and further disease progression is inevitable. While allogeneic stem cell transplant is an attractive option, due to the older age group of T‐PLL patients the morbidity and mortality associated with the procedure is significant.
No Supplementary Data
No Article Media
Document Type: Research Article
Affiliations: Haemato-oncology Unit, The Royal Marsden Hospital, London, UK
Publication date: June 1, 2008